Our fight starts by diagnosing bacterial resistance to antibiotics in record time, using microfluidics.
Our test will help doctors determine the most appropriate antibiotic treatment for their patients and provide same-day results, which will reduce the spread of resistant bacteria and significantly lower the burden on healthcare costs.
This revolutionary scientific development is supported by a Proof of Concept from the lab of Prof. Levenberg, Dean of the Technion Biomedical Engineering Faculty.
Diane Abensur is a Franco-Israeli entrepreneur and the CEO & co-founder of Nanosynex. She established the company in 2017 after graduating from the Technion Institute of Technology International M.B.A (Haifa, Israel). She graduated from E.D.H.E.C Business School (Lille, France) and obtained her Master Degree in Business Management. In between, she worked as a junior analyst in consulting and M&A on healthcare deals in Paris and New York.
TechsoMed is an Israeli based medical device company, developing BioTrace™, a real-time, monitoring and control system for thermal ablation procedures. The technology is applicable to multiple fields such as Oncology (tumor ablation), Cardiac (arrhythmia) and Pain management. Our breakthrough technology (based on two granted patents) is the only one which can give physicians real time monitoring and control for ablation procedures, and it can do all that by interfacing with standard ultrasound devices. The control and security we can give physicians will make our system a must-have for major ablation treatments.
BioTrace™ - Transforming the way Thermal ablations are doneBioTrace – IO World’s first real time monitoring and control system for thermal ablation procedures such as solid tumors.
Interfacing with standard ultrasound devices that can be found in almost every clinic / hospital around the world.
Does not change the way the ablation procedure is done, allowing for fast regulatory approval.
Closed loop treatments with continuous feedback to measure therapy outcomes and to achieve the desired results.
successfully advanced through proof of concept , working prototype and clinical trials – 37 successful humans cases.
RetiCare IVS – Setting the sight on new treatments for retinal diseases
RetiCare is a Danish biotech start-up company focusing on developing new neuroprotective treatments for eye disorders. The company has established in-house a highly translational animal model with end-points that are similar to the diagnostic tool applied in human clinical ophthalmology.
The primary focus is on continuing the development of a new peptide treatment with a novel target discovered and characterized by RetiCare’s founders, which induces neuroprotective effects in the retina. The translational setup will also be used to insource and screen new projects with other targets.
Based on existing data and clinical development feasibility the selected initial indication is retinal detachment, but the indication can upon proof-of concept be expanded to include other indications with involvement death of retinal cells such as glaucoma, age-related macula degeneration, diabetic macular edema, and others.
The team behind RetiCare has in combination several decades of experiences within ophthalmological diseases, neuroprotective effects, clinical practice, and life-science entrepreneurship.
1 in 3 people will develop cancer during their lifetime, and over 90% of cancer patient deaths are caused when the cancer spreads though the body, a process called metastasis. We have identified an excellent anti-metastatic target for therapy development. Extensive pre-clinical models have shown therapeutic efficacy of targeting an enzyme called Lysyl oxidase (LOX). In addition, LOX expression is clinically correlated with metastasis and poor survival in cancer patients. Moreover, LOX is implicated in fibrosis and initial pre-clinical studies suggest LOX may also be an effective therapeutic target for limiting fibrosis. We are currently developing new antibodies against LOX that we are testing pre-clinically with the intention to move into clinical trials in human patients. Our work thus has great potential to develop new effective therapies of commercial value, and offers a real potential to impact on patient well being and survival.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
ADCendo is a biotech start-up company based on a novel cancer drug, invented by the company founders. The drug is an antibody-drug conjugate (ADC), targeting cancer types that currently cannot be cured. • Unmet need: Targeted therapy against sarcomas (primary bone cancer and soft tissue tumors), glioblastomas (GBM; the most malignant brain tumors) and certain types of leukemia • Product: Antibody-drug-conjugate (ADC) against the collagen receptor uPARAP , with proven in vitro efficiency against cell lines of the cancer types mentioned, and convincing in vivo proof of concept in a model of solid cancer. For sarcomas, no efficient treatment exists if metastasis has occurred. GBM is an extremely aggressive type of cancer and is incurable. For leukemia, some sub-types can be treated but relapse is common, mortality still high and additional treatment options are strongly needed.
Actual status: • Proof of concept of receptor-specific and potent killing of sarcoma, GBM and leukemic cells has been obtained in vitro • Very high efficiency and wide window of specificity • A 100 % cure rate obtained in mice with transplanted human tumor cells, with no adverse effects observed • Priority-founding patent applications filed • Commercialization process supported by pre-seed grant from Novo Seeds, Denmark • Company ADCendo has been founded • Ideal scientific and clinical network, with founders based in university and hospital positions • Contact established with key opinion leaders • Pre-clinical and early clinical development plan in place
Paul Biondi is currently senior vice president, Head of Business Development for Bristol-Myers Squibb responsible for leading the development of strategic partnerships and pursuing external scientific innovations across commercial, development, discovery and technology platforms to complement the company’s internal R&D pipeline. With deep knowledge of the company’s R&D strategy and portfolio, strong business expertise and understanding of the healthcare landscape, Paul is focused on external innovation that helps Bristol-Myers Squibb develop and deliver transformational medicines for patients with serious diseases.
Prior to this recent appointment, Paul led the R&D Operations organization at Bristol-Myers Squibb for 10 years working for the Head of R&D at BMS and providing strategic insights and operational excellence to enhance the performance of the R&D organization. As head of R&D Operations he was responsible for optimizing the delivery of the company’s pipeline, managing the company’s R&D portfolio and delivering early- and late-stage clinical operations. He also had responsibility for cross R&D efforts around strategy, analytics, continuous improvement, learning and collaboration. In this role, Paul worked closely with the Business Development leaders in formulating portfolio and disease specific strategies as well as overseeing all integrations of any scientific assets or R&D companies.
Biondi joined Bristol-Myers Squibb in 2002 and was appointed vice president of R&D
Operations when it was formed in May 2005. He was promoted to senior vice president of R&D Operations in 2010. Paul was appointed senior vice president, Head of Business Development in October 2015.
Biondi holds a bachelor’s degree in government and economics from Dartmouth College and an M.B.A. from J.L. Kellogg School of Management at Northwestern University.
Head of Business Development Strategy and Operations
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.
We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.
DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.
RetinAI Medical is a Swiss company that supports eye care professionals and patients throughout the medical examination process using Artificial Intelligence (AI). Our vision is to foster the transition from reactive medicine to preventive medicine for high-impact diseases such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma.
Our solutions rely on the latest advances in medical image analysis, ophthalmology and machine learning. We have a unique team of scientists working to fully realize the capabilities of AI, and to integrate this technology into the next generation of medical devices.